Literature DB >> 19917295

E6 proteins from diverse papillomaviruses self-associate both in vitro and in vivo.

Katia Zanier1, Christine Ruhlmann, Frederic Melin, Murielle Masson, Abdellahi Ould M'hamed Ould Sidi, Xavier Bernard, Benoit Fischer, Laurent Brino, Tutik Ristriani, Vladimir Rybin, Mireille Baltzinger, Scott Vande Pol, Petra Hellwig, Patrick Schultz, Gilles Travé.   

Abstract

Papillomavirus E6 oncoproteins bind and often provoke the degradation of many cellular proteins important for the control of cell proliferation and/or cell death. Structural studies on E6 proteins have long been hindered by the difficulties of obtaining highly concentrated samples of recombinant E6. Here, we show that recombinant E6 proteins from eight human papillomavirus strains and one bovine papillomavirus strain exist as oligomeric and multimeric species. These species were characterized using a variety of biochemical and biophysical techniques, including analytical gel filtration, activity assays, surface plasmon resonance, electron microscopy and Fourier transform infrared spectroscopy. The characterization of E6 oligomers is facilitated by the fusion to the maltose binding protein, which slows the formation of higher-order multimeric species. The proportion of each oligomeric form varies depending on the viral strain considered. Oligomers appear to consist of folded units, which, in the case of high-risk mucosal human papillomavirus E6, retain binding to the ubiquitin ligase E6-associated protein and the capacity to degrade the proapoptotic protein p53. In addition to the small-size oligomers, E6 proteins spontaneously assemble into large organized multimeric structures, a process that is accompanied by a significant increase in the beta-sheet secondary structure content. Finally, co-localisation experiments using E6 equipped with different tags further demonstrate the occurrence of E6 self-association in eukaryotic cells. The ensemble of these data suggests that self-association is a general property of E6 proteins that occurs both in vitro and in vivo and might therefore be functionally relevant. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19917295      PMCID: PMC3900769          DOI: 10.1016/j.jmb.2009.11.022

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  39 in total

1.  Cloning, expression, and transcriptional properties of the human enhancer factor TEF-1.

Authors:  J H Xiao; I Davidson; H Matthes; J M Garnier; P Chambon
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

2.  Targeting and degradation of p53 by E6 of human papillomavirus type 16 is preferential for the 1620+ p53 conformation.

Authors:  E A Medcalf; J Milner
Journal:  Oncogene       Date:  1993-10       Impact factor: 9.867

3.  Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein.

Authors:  T Kiyono; A Hiraiwa; M Fujita; Y Hayashi; T Akiyama; M Ishibashi
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

4.  Identification of an alpha helical motif sufficient for association with papillomavirus E6.

Authors:  J J Chen; Y Hong; E Rustamzadeh; J D Baleja; E J Androphy
Journal:  J Biol Chem       Date:  1998-05-29       Impact factor: 5.157

5.  Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.

Authors:  C Giovane; G Trave; A Briones; Y Lutz; B Wasylyk; E Weiss
Journal:  J Mol Recognit       Date:  1999 Mar-Apr       Impact factor: 2.137

6.  Molecular analysis of the interaction between HPV type 16 E6 and human E6-associated protein.

Authors:  P R Daniels; C M Sanders; P Coulson; N J Maitland
Journal:  FEBS Lett       Date:  1997-10-13       Impact factor: 4.124

7.  Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.

Authors:  D Pim; P Massimi; L Banks
Journal:  Oncogene       Date:  1997-07-17       Impact factor: 9.867

8.  Interaction of the bovine papillomavirus E6 protein with the clathrin adaptor complex AP-1.

Authors:  X Tong; W Boll; T Kirchhausen; P M Howley
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

9.  The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton.

Authors:  X Tong; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-29       Impact factor: 11.205

10.  Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group.

Authors:  F X Bosch; M M Manos; N Muñoz; M Sherman; A M Jansen; J Peto; M H Schiffman; V Moreno; R Kurman; K V Shah
Journal:  J Natl Cancer Inst       Date:  1995-06-07       Impact factor: 13.506

View more
  18 in total

1.  Identification and proteomic analysis of distinct UBE3A/E6AP protein complexes.

Authors:  Gustavo Martínez-Noël; Jeffrey T Galligan; Mathew E Sowa; Verena Arndt; Thomas M Overton; J Wade Harper; Peter M Howley
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

2.  Stepwise multipolyubiquitination of p53 by the E6AP-E6 ubiquitin ligase complex.

Authors:  Yuji Masuda; Yasushi Saeki; Naoko Arai; Hidehiko Kawai; Iwao Kukimoto; Keiji Tanaka; Chikahide Masutani
Journal:  J Biol Chem       Date:  2019-09-06       Impact factor: 5.157

3.  Solution structure analysis of the HPV16 E6 oncoprotein reveals a self-association mechanism required for E6-mediated degradation of p53.

Authors:  Katia Zanier; Abdellahi ould M'hamed ould Sidi; Charlotte Boulade-Ladame; Vladimir Rybin; Anne Chappelle; Andrew Atkinson; Bruno Kieffer; Gilles Travé
Journal:  Structure       Date:  2012-04-03       Impact factor: 5.006

4.  Strategies for bacterial expression of protein-peptide complexes: application to solubilization of papillomavirus E6.

Authors:  Abdellahi Ould M'hamed Ould Sidi; Khaled Ould Babah; Nicole Brimer; Yves Nominé; Christophe Romier; Bruno Kieffer; Scott Vande Pol; Gilles Travé; Katia Zanier
Journal:  Protein Expr Purif       Date:  2011-07-14       Impact factor: 1.650

5.  Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins.

Authors:  Katia Zanier; Sebastian Charbonnier; Abdellahi Ould M'hamed Ould Sidi; Alastair G McEwen; Maria Giovanna Ferrario; Pierre Poussin-Courmontagne; Vincent Cura; Nicole Brimer; Khaled Ould Babah; Tina Ansari; Isabelle Muller; Roland H Stote; Jean Cavarelli; Scott Vande Pol; Gilles Travé
Journal:  Science       Date:  2013-02-08       Impact factor: 47.728

6.  Parallel β-sheet vibrational couplings revealed by 2D IR spectroscopy of an isotopically labeled macrocycle: quantitative benchmark for the interpretation of amyloid and protein infrared spectra.

Authors:  Ann Marie Woys; Aaron M Almeida; Lu Wang; Chi-Cheng Chiu; Michael McGovern; Juan J de Pablo; James L Skinner; Samuel H Gellman; Martin T Zanni
Journal:  J Am Chem Soc       Date:  2012-11-09       Impact factor: 15.419

7.  The active form of E6-associated protein (E6AP)/UBE3A ubiquitin ligase is an oligomer.

Authors:  Virginia P Ronchi; Jennifer M Klein; Daniel J Edwards; Arthur L Haas
Journal:  J Biol Chem       Date:  2013-11-22       Impact factor: 5.157

8.  Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand.

Authors:  Juan Ramirez; Juline Poirson; Clémence Foltz; Yassmine Chebaro; Maxime Schrapp; Amandine Meyer; Anaëlle Bonetta; Anne Forster; Yves Jacob; Murielle Masson; François Deryckère; Gilles Travé
Journal:  Angew Chem Int Ed Engl       Date:  2015-05-27       Impact factor: 15.336

9.  Patterns Prediction of Chemotherapy Sensitivity in Cancer Cell lines Using FTIR Spectrum, Neural Network and Principal Components Analysis.

Authors:  Rezvan Zendehdel; Ali Masoudi-Nejad; Farshad H Shirazi
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

10.  Discrimination of Human Cell Lines by Infrared Spectroscopy and Mathematical Modeling.

Authors:  Rezvan Zendehdel; Farshad H Shirazi
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.